-

New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence

  • Among dry eye sufferers who said their stress or anxiety levels were affected, most (73%) reported improvement following treatment
  • While some sufferers (22%) were aware that dry eye symptoms could be associated with autoimmune conditions in general, less than 10% were aware that symptoms could be associated with type 1 diabetes, lupus or rheumatoid arthritis specifically
  • Third annual survey continues to uncover new insights related to living with dry eye

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced new findings from its third annual State of Dry Eye survey, which reveals that the impact of dry eye can extend beyond the burden of physical symptoms, affecting how patients view their emotional health and wellbeing. This year’s survey was conducted online by The Harris Poll in May 2026 among 1,000 dry eye sufferers who were using either a prescription treatment or an over-the-counter (OTC) product.

“We know from our previous State of Dry Eye surveys that the physical symptoms of dry eye present challenges in everyday life, and the newest findings reveal another profound burden: a noticeable impact on emotional health and well-being,” said Andrew Stewart, president, Global Pharmaceuticals and International Consumer, Bausch + Lomb. “These insights reinforce that dry eye is a complex condition and addressing symptoms not only provides physical relief – it helps patients feel better holistically. We urge anyone who is suffering to speak with an eye care professional."

New findings show that one in five sufferers reported dry eye symptoms affect their self-confidence (22%) and emotional wellbeing (20%). Additionally, about one in three stated their dry eye symptoms affect their stress/anxiety level (33%), and nearly three in ten reported impacts to productivity (29%) and mood (28%).

The survey also explores the impact of dry eye management either with a prescription treatment or an OTC product. Overall, sufferers treated with prescription eye drops were more likely to report near-total or substantial improvement in various aspects of life after starting treatment:

  • Approximately six in 10 prescription users reported improved self-confidence (64% vs 25% of OTC users*) and productivity (60% vs 43% OTC)
  • More than half of prescription users reported improved emotional wellbeing (59% vs 34% OTC*) and mood (52% vs 38% OTC).

*OTC only base n<100

Additionally, the survey highlights a lack of awareness of how dry eye symptoms may be linked to hormonal changes and systemic inflammation from co-existing conditions:

  • Nine in 10 (90%) sufferers did not know that dry eye symptoms may be associated with menopause
  • Nearly eight in 10 sufferers did not know dry eye symptoms could be associated with autoimmune conditions (78%); specifically:
    • Only 8% of sufferers knew dry eye symptoms could be associated with lupus
    • Only 8% of sufferers knew dry eye symptoms could be associated with type 1 diabetes
    • Only 7% of sufferers knew dry eye symptoms could be associated with rheumatoid arthritis.

For more information about dry eye, visit www.KnowYourDryEye.com.

About Dry Eye
Dry eye can be influenced by several factors, including lifestyle, medications, hormonal changes, age, environment and co-morbidities. It may be the result of the eyes not making enough tears or making poor quality tears that evaporate too quickly. The majority of those who progress to dry eye disease also have underlying inflammation. There are a range of options for managing dry eye symptoms, including over-the-counter eye drops, prescription medications and nutritional supplements.

About the Survey
The research was conducted online in the U.S. by The Harris Poll on behalf of Bausch + Lomb among 1,000 U.S. adults aged 18 or older considered “DED sufferers” (defined as those who often/always experience eye dryness or have been diagnosed by a healthcare professional with dry eye disease). Of those, 411 take only an over-the-counter product to treat their dry eye and 589 take a prescription medication for their dry eye. The survey was conducted between May 4 and May 15, 2026. For complete methodology, please contact Bausch + Lomb.

About Bausch + Lomb
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

©2026 Bausch + Lomb.
BLNP.0049.USA.26

Contacts

Media Contact:
Caryn Marshall
caryn.marshall@bausch.com
(908) 493-1381

Bausch + Lomb Corporation

NYSE:BLCO

Release Versions

Contacts

Media Contact:
Caryn Marshall
caryn.marshall@bausch.com
(908) 493-1381

More News From Bausch + Lomb Corporation

Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink Triple Care Preservative Free eye drops, which provide instant, long-lasting relief for dry eyes without the use of preservatives and are packaged in a multi-dose bottle. Blink Triple Care Preservative Free is made with the same clinically proven formula as Blink Triple Care, helping red...

Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of Research and Development Yehia Hashad, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, on Tuesday, June 9, 2026, at 1:20 p.m. ET. A live webcast of the session will be av...

Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2026 annual meeting of shareholders (the “Annual Meeting”) held on May 20, 2026. The detailed results of the vote for the election of directors are set out below: Name For Against Broker Non-Votes Eduardo Alfonso, M.D. 331,573,622 4,244,069 11,452,072 Nathalie Be...
Back to Newsroom